Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220023/S012

Paradise Ultrasound Renal Denervation System (Paradise System); Paradise Catheter

Recor Medical, Inc. · Decision date Jul 29, 2026

FDA DECISIONP220023/S012

What did the FDA decide?

FDA records P220023/S012 as a supplement to PMA P220023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 29, 2026.

FDA approval order statement

approval for changes to the manufacturing process of the ultrasound transducer
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jul 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220023/S012
Regulatory pathway
PMA supplement
Product code
QYI
Decision code
OK30
Decision date
Jul 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation catheter, renal denervation.

Product code
QYI
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220023/S009 · Related supplement

    ReCor Paradise Catheter

  2. P220023/S012 received

    Application receipt date recorded by FDA.

  3. P220023/S012 · FDA decision

    30-Day Notice

  4. P220023/S011 · Related supplement

    Paradise Ultrasound Renal Denervation System (Paradise System)

Timeline entries are records held by MedtechLedger for P220023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220023

Product / regulatory recordCompanyPathwayDecision dateSource
Recor Medical, Inc.PMA supplementSep 11, 2025FDA
Recor Medical, Inc.PMA supplementAug 13, 2026FDA

Explore the linked device profile

Other records with product code QYI

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementSep 10, 2026FDA
Medtronic, Inc.PMA supplementJul 16, 2026FDA
Medtronic, Inc.PMA supplementMar 25, 2026FDA
Medtronic, Inc.PMA supplementFeb 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Recor Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1049 Elwell Ct., Palo Alto, CA, 94303

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records